App-Based Certified Diabetes Education Therapy (AB-CDE)

Part of paid clinical trials in Los Angeles, California.

Sponsor
Oregon Health and Science University
Study ID
NCT07282639
Status
Recruiting
Apply to this trial

Conditions

  • Type 1 Diabetes (T1D)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • DailyDose — DEVICE
    Our team has developed a smartphone-based application, DailyDose Decision Support Tool (DailyDose), that combines continuous glucose monitoring data and insulin data to provide decision support for people living with T1D taking MDI. DailyDose is an iPhone application that is designed to support this population by 1) allowing for bolus calculation based on inputs including carbohydrate intake, CGM value and trend, and exercise information, 2) providing recommendations for carbohydrate intake based on exercise type, intensity, and duration, and 3) providing weekly recommendations for adjustments in insulin doses at specific times of day, including basal insulin dose, carbohydrate ratios or fixed mealtime doses, and correction factors .

Study Details

The purpose of this study is to learn more about a smartphone application (app) called DailyDose, an investigational decision support tool that may help in managing your diabetes. DailyDose tracks your continuous glucose monitoring (CGM) data, insulin use, and exercise, and uses this information to provide personalized recommendations for insulin dosing and carbohydrate intake during exercise or low blood sugar events. We want to find out if DailyDose can help lower blood sugar levels as measured by the hemoglobin A1c (HbA1c) test.

Key Dates

First listed
Dec 15, 2025
Start date
Jul 8, 2026
Status verified
Sep 2026
Primary completion
Jul 15, 2027
Completion
Dec 15, 2027

Study Design

Enrollment
99 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Intervention Group
    AB-CDE intervention using DailyDose, study CGM, and CDE and BH counselling if indicated
  • No Intervention: Control Group
    Usual care including MDI insulin therapy with study CGM and DailyDose in Data-logging Mode.

Primary Outcome Measure

Change in hemoglobin A1c (HbA1c) from baseline to 24 weeks [ Time Frame: Enrollment and 24 weeks after randomization ]

Central Contacts

Locations (6)

FacilityCityStateZIPSite coordinators
University of Southern CaliforniaLos AngelesCalifornia90022
Anna Peters, MD
[email protected]
323-362-1320
Valerie Ruelas
[email protected]
Barbara Davis CenterAuroraColorado80045
Halis Akturk, MD
[email protected]
303-724-0467
Emma Mason
[email protected]
303-724-5895
Indiana UniversityIndianapolisIndiana46202
Viral Shah, MD
[email protected]
317-274-7605
Brittany Thorne
[email protected]
317-278-0532
Joslin Diabetes Center, Harvard School of MedicineBostonMassachusetts02215
Joslin Toschi, MD
[email protected]
617-309-2440
Christine Slyne
[email protected]
Mount Sinai School of MedicineNew YorkNew York10029
Carol Levy, MD
[email protected]
212-241-0068
Sarah Rancic
[email protected]
Camilla Levister (SUB_INVESTIGATOR)
Oregon Health & Science University , PortlandPortlandOregon97239
Linda Lester, MD
[email protected]
503-418-8478
Peter Jacobs, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By research site
University of Southern California· Los Angeles, CABarbara Davis Center· Aurora, COIndiana University· Indianapolis, INJoslin Diabetes Center, Harvard School of Medicine· Boston, MAMount Sinai School of Medicine· New York, NYOregon Health & Science University , Portland· Portland, OR

Related Studies